Collegium Pharmaceutical (NASDAQ:COLL) Upgraded to “Buy” at Jefferies Financial Group

Jefferies Financial Group upgraded shares of Collegium Pharmaceutical (NASDAQ:COLLFree Report) from a hold rating to a buy rating in a research report released on Friday morning, MarketBeat.com reports. They currently have $44.00 target price on the specialty pharmaceutical company’s stock, up from their prior target price of $41.00.

A number of other analysts have also recently commented on the company. Piper Sandler cut Collegium Pharmaceutical from an overweight rating to a neutral rating and set a $39.00 price target for the company. in a research note on Friday, May 10th. Truist Financial upped their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a buy rating in a research note on Monday, February 26th. Needham & Company LLC cut Collegium Pharmaceutical from a buy rating to a hold rating in a research note on Friday, May 10th. Finally, StockNews.com cut Collegium Pharmaceutical from a strong-buy rating to a buy rating in a research note on Wednesday, May 1st. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $40.75.

Check Out Our Latest Report on COLL

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL opened at $33.19 on Friday. The stock has a market capitalization of $1.09 billion, a P/E ratio of 13.83 and a beta of 0.96. Collegium Pharmaceutical has a 1-year low of $20.83 and a 1-year high of $40.95. The company has a current ratio of 1.21, a quick ratio of 1.14 and a debt-to-equity ratio of 1.98. The business has a 50-day moving average price of $35.41 and a two-hundred day moving average price of $33.68.

Collegium Pharmaceutical (NASDAQ:COLLGet Free Report) last announced its quarterly earnings data on Thursday, May 9th. The specialty pharmaceutical company reported $1.32 earnings per share for the quarter, missing the consensus estimate of $1.36 by ($0.04). The firm had revenue of $144.92 million for the quarter, compared to the consensus estimate of $147.04 million. Collegium Pharmaceutical had a return on equity of 104.98% and a net margin of 16.46%. Equities analysts predict that Collegium Pharmaceutical will post 5.67 earnings per share for the current year.

Insider Activity at Collegium Pharmaceutical

In related news, CFO Colleen Tupper sold 19,710 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the completion of the transaction, the chief financial officer now directly owns 130,845 shares in the company, valued at approximately $4,476,207.45. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $32.30, for a total transaction of $936,215.50. Following the completion of the transaction, the director now owns 44,775 shares of the company’s stock, valued at approximately $1,446,232.50. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO Colleen Tupper sold 19,710 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $34.21, for a total value of $674,279.10. Following the transaction, the chief financial officer now directly owns 130,845 shares of the company’s stock, valued at approximately $4,476,207.45. The disclosure for this sale can be found here. In the last three months, insiders sold 105,502 shares of company stock worth $3,540,796. 3.98% of the stock is owned by company insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in Collegium Pharmaceutical by 0.8% during the 1st quarter. Vanguard Group Inc. now owns 2,330,728 shares of the specialty pharmaceutical company’s stock worth $90,479,000 after acquiring an additional 17,942 shares during the last quarter. Pacer Advisors Inc. boosted its position in Collegium Pharmaceutical by 68.4% during the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock worth $66,938,000 after acquiring an additional 883,380 shares during the last quarter. Invesco Ltd. boosted its position in Collegium Pharmaceutical by 1.7% during the 3rd quarter. Invesco Ltd. now owns 1,159,604 shares of the specialty pharmaceutical company’s stock worth $25,917,000 after acquiring an additional 19,740 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Collegium Pharmaceutical by 2.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,039,218 shares of the specialty pharmaceutical company’s stock worth $31,987,000 after acquiring an additional 29,529 shares during the last quarter. Finally, LSV Asset Management boosted its holdings in shares of Collegium Pharmaceutical by 188.7% in the 1st quarter. LSV Asset Management now owns 380,551 shares of the specialty pharmaceutical company’s stock valued at $14,773,000 after buying an additional 248,751 shares during the last quarter.

Collegium Pharmaceutical Company Profile

(Get Free Report)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.

Recommended Stories

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.